Abstract
Twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART)with moderate-advanced Kaposi's sarcoma (KS)were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin(PLD) or the new HAART regimen alone. After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antiretroviral Therapy, Highly Active / methods*
-
Doxorubicin / administration & dosage*
-
Drug Therapy, Combination
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
Humans
-
Liposomes
-
Male
-
Middle Aged
-
Sarcoma, Kaposi / complications
-
Sarcoma, Kaposi / drug therapy*
-
Skin Neoplasms / complications
-
Skin Neoplasms / drug therapy
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Liposomes
-
Doxorubicin